Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ionis Pharmaceutical (IONS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 7,604,614
  • Shares Outstanding, K 124,360
  • Annual Sales, $ 346,620 K
  • Annual Income, $ -86,560 K
  • 36-Month Beta 3.12
  • Price/Sales 21.20
  • Price/Cash Flow 0.00
  • Price/Book 33.99

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.75 +28.06%
on 09/29/17
63.20 -3.24%
on 10/16/17
+1.92 (+3.24%)
since 09/15/17
3-Month
43.75 +39.77%
on 08/11/17
63.20 -3.24%
on 10/16/17
+9.55 (+18.51%)
since 07/14/17
52-Week
24.58 +148.78%
on 11/02/16
63.20 -3.24%
on 10/16/17
+32.15 (+110.86%)
since 10/14/16

Most Recent Stories

More News
Today's Research Reports on Trending Tickers: EnteroMedics and Ionis Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / October 17, 2017 / All three major indexes notched record closes on Monday setting a positive tone for an important week of corporate earnings. The Dow Jones Industrial Average...

IBM : 146.70 (-0.09%)
JNJ : 135.80 (-0.24%)
PG : 93.30 (+0.17%)
AXP : 91.96 (-0.97%)
IONS : 61.15 (+3.47%)
ETRM : 2.21 (-1.34%)
GS : 245.99 (+1.48%)
GE : 23.28 (-0.34%)
UNH : 196.40 (+1.66%)
Featured Company News - Ionis Pharma Commences Phase-1/2a Clinical Study of IONIS-MAPTRx for Patients with Alzheimer's Disease

LONDON, UK / ACCESSWIRE / October 16, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), following which...

IONS : 61.15 (+3.47%)
Akcea Presents Data Demonstrating Significant Burden of Illness in Familial Chylomicronemia Syndrome

Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid...

AKCA : 22.39 (-2.82%)
IONS : 61.15 (+3.47%)
Ionis Presents New Data from NEURO-TTR Study and Highlights Programs from Its Neurological Disease Franchise at ANA Congress

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that new data from the Phase 3 NEURO-TTR study with inotersen in patients with hereditary TTR amyloidosis...

IONS : 61.15 (+3.47%)
Ionis Pharmaceuticals Initiates Clinical Study of IONIS-MAPT Rx in Patients with Alzheimer's Disease

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has initiated a Phase 1/2a clinical study of IONIS-MAPTRx in patients with mild Alzheimer's disease (AD). Ionis earned a $10 million milestone...

IONS : 61.15 (+3.47%)
Akcea Therapeutics' Volanesorsen Receives Promising Innovative Medicine (PIM) Status for the Treatment of Familial Chylomicronaemia Syndrome (FCS)

LONDON, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics United Kingdom (UK) today announced that volanesorsen has been granted a Promising Innovative Medicine (PIM) Designation by the Medicines and...

AKCA : 22.39 (-2.82%)
IONS : 61.15 (+3.47%)
Today's Research Reports on Trending Tickers: Ionis Pharmaceuticals and HTG Molecular Diagnostics

NEW YORK, NY / ACCESSWIRE / October 6, 2017 / Financials and information technology stocks lifted the S&P 500 Index to its sixth consecutive record close and its first 8-day win streak since 2013. The...

HTGM : 2.36 (+4.89%)
IONS : 61.15 (+3.47%)
Biogen's SPINRAZA(R) (nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with Spinal Muscular Atrophy

--Phase 2 EMBRACE interim analysis showed greater motor milestone achievement in infants and children treated with SPINRAZA, compared to those untreated, in patient populations not studied in the pivotal...

IONS : 61.15 (+3.47%)
BIIB : 342.00 (+1.88%)
Akcea Therapeutics Canada Appoints Nelly Komari, B. Pharm., MSc. as Medical Director

Akcea Therapeutics Canada is pleased to announce the appointment of Nelly Komari, B. Pharm., MSc., as Medical Director. Akcea Therapeutics Canada, the Canadian subsidiary of Akcea Therapeutics, Inc.,...

AKCA : 22.39 (-2.82%)
IONS : 61.15 (+3.47%)
Breakfast Technical Briefing on Drug Makers Stocks -- Amarin, Endo, Ionis Pharma, and Teva Pharma

If you want a Stock Review on AMRN, ENDP, IONS, or TEVA then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. This morning, DailyStockTracker.com redirects...

ENDP : 7.70 (+1.05%)
AMRN : 3.32 (+0.30%)
IONS : 61.15 (+3.47%)
TEVA : 14.78 (+0.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California.

See More

Support & Resistance

2nd Resistance Point 65.36
1st Resistance Point 63.25
Last Price 61.15
1st Support Level 58.99
2nd Support Level 56.84

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart